4-iso-propyl-2-methylpyridine | 13854-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-iso-propyl-2-methylpyridine
• 英文别名: 4-isopropyl-2-methylpyridine；4-isopropyl-2-methyl-pyridine；4-Isopropyl-2-methyl-pyridin；4-Isoproppyl-2-methyl-pyridin；Pyridine, 2-methyl-4-(1-methylethyl)；2-methyl-4-propan-2-ylpyridine
• CAS: 13854-03-0
• 化学式: C₉H₁₃N
• 分子量: 135.209
• InChiKey: YWVVIBOXHWIQMY-UHFFFAOYSA-N

物化性质

• 沸点：
  98-99 °C(Press: 40 Torr)
• 密度：
  0.907±0.06 g/cm3(Predicted)
• 保留指数：
  1056;1059

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-iso-propyl-2-methylpyridine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 36.25h， 生成 2-cyano-4-iso-propyl-6-methylpyridine
  参考文献：
  名称：

  Exquisite sensitivity of the ligand field to solvation and donor polarisability in coordinatively saturated lanthanide complexes

  摘要：

  第二配位层确定了镧系配位化合物中的配体场。

  DOI：

  10.1039/c8cc04995e
• 作为产物：
  描述：

  4-溴-2-甲基吡啶 在 copper(I) cyanide 、 异丙基氯化镁 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 18.0h， 以53%的产率得到4-iso-propyl-2-methylpyridine
  参考文献：
  名称：

  Exquisite sensitivity of the ligand field to solvation and donor polarisability in coordinatively saturated lanthanide complexes

  摘要：

  第二配位层确定了镧系配位化合物中的配体场。

  DOI：

  10.1039/c8cc04995e

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：US20200247815A1

  公开（公告）日：2020-08-06

  The present invention relates to pyrazolyl-containing tricyclic derivative, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protease such as ERK (MAPK) inhibitor in the treatment of cancers, bone diseases, inflammatory diseases, immunological diseases, nervous system diseases, metabolic diseases, respiratory diseases and heart diseases, wherein the definition of each substituent in the general formula (1) is the same as defined in the description.

  本发明涉及吡唑基含有的三环衍生物，其制备方法及其用途。具体而言，本发明涉及一种如通式(I)所示的化合物，其制备方法及含有该化合物的药物组合物，以及将其用作蛋白酶，如ERK（MAPK）抑制剂，用于治疗癌症、骨疾病、炎症性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸系统疾病和心脏疾病，其中通式（1）中每个取代基的定义与描述中定义的相同。
• PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
  申请人：Hadida Ruah Sara Sabina

  公开号：US20120196869A1

  公开（公告）日：2012-08-02

  The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• Ir₄(CO)₁₂-Catalyzed Benzylic C(sp³)–H Silylation of 2-Alkylpyridines with Hydrosilanes Leading to 2-(1-Silylalkyl)pyridines
  作者：Yoshiya Fukumoto、Masaya Hirano、Nao Matsubara、Naoto Chatani

  DOI：10.1021/acs.joc.7b02375

  日期：2017.12.15

  The iridium-catalyzed C(sp3)–H silylation of 2-alkylpyridines with hydrosilanes at the benzylic position to afford 2-(1-silylalkyl)pyridines is described. The low product yield was markedly improved by adding 3,5-dimethylpyridine. Norbornene is also an essential additive for the reaction to proceed as a hydrogen scavenger. Carbon monoxide plays an important role in the catalytic cycle as a ligand.

  描述了铱催化的2-烷基吡啶的C（sp 3）-H甲硅烷基化，以及在苄基位置的氢硅烷提供2-（1-甲硅烷基烷基）吡啶。通过加入3，5-二甲基吡啶显着提高了低产物收率。降冰片烯也是作为氢清除剂进行的反应的必要添加剂。一氧化碳作为配体在催化循环中起着重要作用。其他的过渡金属羰基化合物，例如Rh 4（CO）12和Ru 3（CO）12也可以用作C–H甲硅烷基化的催化剂。